Sanofi prunes its pipeline, tak­ing the ax to a line­up of drug, vac­cine pro­grams

Sanofi swept away a line­up of drug and vac­cine pro­grams in its Q2 up­date, start­ing with a late-stage vac­cine play with Dai­ichi Sankyo and run­ning right through set­backs on their CD38 drug, the an­ti-in­flam­ma­to­ry Kevzara, as well as a trou­bled al­liance with De­nali on ALS.

Gone is a long­stand­ing Phase III de­vel­op­ment pro­gram with Dai­ichi Sankyo for a pe­di­atric pen­tava­lent vac­cine in Japan, though there’s no word on what prompt­ed the pull­back.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER